A First-in-human, Single-ascending-dose Study of IBI3002 in Healthy Participants and Mild to Moderate Asthmatics

NCT ID: NCT06213844

Last Updated: 2025-11-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 52 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-02-26
• Study Completion Date: 2025-09-11

Brief Summary

This is a single-center, randomized, double-blind, placebo-controlled, phase 1, single-ascending-dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of IBI3002 in healthy participants and mild to moderate asthmatics. Subjects will be randomly assigned to different dosages of IBI3002 and matched placebo groups. The entire trial cycle includes a 4-week screening period, 1-day treatment period and 5-week follow-up period.

Conditions

Healthy Participants; Asthma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Placebo

Single dose of Placebo administered subcutaneously on Day 1

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Single dose of Placebo, administered subcutaneously on Day 1

IBI3002

Single dose of IBI3002 (Dosage 1, Dosage 2, Dosage 3, Dosage 4, Dosage 5, Dosage 6) administered subcutaneously on Day 1

Group Type: EXPERIMENTAL

IBI3002

Intervention Type: DRUG

Single dose of IBI3002 (Dosage 1, Dosage 2, Dosage 3, Dosage 4, Dosage 5, Dosage 6), administered subcutaneously on Day 1

Interventions

IBI3002

Single dose of IBI3002 (Dosage 1, Dosage 2, Dosage 3, Dosage 4, Dosage 5, Dosage 6), administered subcutaneously on Day 1

Intervention Type: DRUG

Placebo

Single dose of Placebo, administered subcutaneously on Day 1

Intervention Type: DRUG

Other Intervention Names

ICS, alone or in combination with LABA; ICS, alone or in combination with LABA

Eligibility Criteria

Inclusion Criteria

1. Participants must sign an Institutional Review Board (IRB) approved informed consent form before any study specific procedures.

2. Participants must be between 18 and 55 years old, inclusive.

3. Participants must have a body mass index (BMI) between 18 to 32 kg/m2, inclusive.

4. Participants of childbearing potential and their partners should use highly effective methods of birth control during the study and until 6 months after the study.

5. Participants with asthma must have:

• Documented physician diagnosis of asthma for at least 12 months prior to screening and confirmed by the investigator;
• Elevated FeNO defined as ≥ 25ppb;
• Documented and stable GINA 2023 recommended Step 1~3 controller treatment (defined as ≤ 250μg fluticasone propionate dry powder formulation equivalent total daily dose of ICS, alone or in combination with LABA) for the last 3 months prior to screening;
• Pre-BD FEV1 ≥ 60% of prediction and Post-BD FEV1/forced vital capacity (FVC) > 70%.

Exclusion Criteria

1. History of allergies to any components of IBI3002 or placebo.

2. History of blood or needle sickness, or those who cannot tolerate venipuncture.

3. Female participants who are pregnant or breastfeeding at screening or randomization.

4. History of participating in a clinical trial within 1 month or 5 half-lives of the test drug (whichever is longer) prior to randomization, or those who are currently participating in a clinical trial.

5. History of severe infection or significant injury within 6 months, or surgery within 3 months, or any infection requiring systemic medication within 1 month prior to screening or randomization.

6. History of live or attenuated vaccination within 1 month prior to randomization, or those who plan to be vaccinated during the study.

7. For asthmatics only: history of a life-threatening asthma attack that required mechanical ventilation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures within the last 5 years prior to randomization.

8. For asthmatics only: history of asthma worsen or exacerbation resulting in emergency room (ER) visits or overnight hospitalizations, or an increase in asthma maintenance therapy, or use of systemic glucocorticoids within the last 3 months prior to randomization.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Nucleus Network Pty Ltd

Melbourne, Victoria, Australia

Countries

Australia

Other Identifiers

CIBI3002A101AU

Identifier Type: -

Identifier Source: org_study_id